Dyadic International, Inc. (NASDAQ:DYAI) CEO Sells $85,560.00 in Stock

Dyadic International, Inc. (NASDAQ:DYAI) CEO Mark A. Emalfarb sold 23,000 shares of the business’s stock in a transaction on Wednesday, June 9th. The stock was sold at an average price of $3.72, for a total value of $85,560.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Shares of DYAI stock opened at $3.74 on Friday. Dyadic International, Inc. has a 1 year low of $3.34 and a 1 year high of $10.98. The stock’s fifty day simple moving average is $4.36. The firm has a market cap of $103.05 million and a price-to-earnings ratio of -11.00.

Dyadic International (NASDAQ:DYAI) last announced its quarterly earnings results on Monday, March 29th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.08) by $0.01. Dyadic International had a negative return on equity of 35.81% and a negative net margin of 595.37%. As a group, research analysts expect that Dyadic International, Inc. will post -0.4 EPS for the current fiscal year.

Several institutional investors have recently made changes to their positions in DYAI. Sage Mountain Advisors LLC acquired a new stake in shares of Dyadic International in the fourth quarter valued at $583,000. Axiom Investment Management LLC acquired a new stake in shares of Dyadic International in the first quarter valued at $366,000. JPMorgan Chase & Co. lifted its holdings in shares of Dyadic International by 400.7% in the fourth quarter. JPMorgan Chase & Co. now owns 52,829 shares of the biotechnology company’s stock valued at $284,000 after buying an additional 42,277 shares during the period. BlackRock Inc. lifted its holdings in shares of Dyadic International by 2.8% in the fourth quarter. BlackRock Inc. now owns 1,272,712 shares of the biotechnology company’s stock valued at $6,848,000 after buying an additional 35,023 shares during the period. Finally, Trexquant Investment LP acquired a new stake in shares of Dyadic International in the fourth quarter valued at $158,000. Institutional investors and hedge funds own 19.71% of the company’s stock.

Dyadic International Company Profile

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins.

Featured Article: How does a security become overbought?

Receive News & Ratings for Dyadic International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyadic International and related companies with MarketBeat.com's FREE daily email newsletter.